Q32 Bio announced that it has completed enrollment in the SIGNAL-AD Phase 2 clinical trial of bempikibart for the treatment of persistent, moderate-to-severe atopic dermatitis, or AD. Bempikibart is a fully human anti-IL-7Ra antibody that is designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling, both of which contribute to inflammation and injury in a diversity of autoimmune disorders.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTTB:
Questions or Comments about the article? Write to editor@tipranks.com